Repros Seeks To Develop Low-Dose Proellex To Avoid Liver Toxicity
This article was originally published in The Pink Sheet Daily
Executive Summary
In a precarious financial situation, the company requests that FDA lift a clinical hold on the drug it is developing for uterine fibroids and endometriosis.